“Some days I wake up and can’t believe that how far we’ve come,” reported Dr. Doblin, 67, who now oversees the Multidisciplinary Association for Psychedelic Studies, a multimillion greenback research and advocacy empire that employs 130 neuroscientists, pharmacologists and regulatory experts Doing the job to lay the groundwork for the comin